Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity

Journal of Virology

Volumn 78, Issue 6, 2004, Pages 3123-3132

  Logsdon, Bradley C ^a   Vickrey, John F ^a   Martin, Philip ^a   Proteasa, Gheorghe ^a   Koepke, Jay I ^a   Terlecky, Stanley R ^a   Wawrzak, Zdzislaw ^b   Winters, Mark A ^c   Merigan, Thomas C ^c   Kovari, Ladislau C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR; MOZENAVIR; NELFINAVIR; PALINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVE SITE; ENZYME PURIFICATION; ENZYME STRUCTURE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; VIRUS ISOLATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PYRIMIDINONES;

EID: 12144286765     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.6.3123-3132.2004     Document Type: Article

References (56)

1. Ala, P. J., R. J. DeLoskey, E. E. Huston, P. K. Jadhav, P. Y. Lam, C. J. Eyermann, C. N. Hodge, M. C. Schadt, F. A. Lewandowski, P. C. Weber, D. D. McCabe, J. L. Duke, and C. H. Chang. 1998. Molecular recognition of cyclic urea HIV-1 protease inhibitors. J. Biol. Chem. 273:12325-12331.
2. Blundell, T. L., R. Lapatto, A. F. Wilderspin, A. M. Hemmings, P. M. Hobart, D. E. Danley, and P. J. Whittle. 1990. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. Trends Biochem. Sci. 15:425-430.
3. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
4. Carpenter, C. C., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:381-390.
5. D'Aquila, R., J. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L. Demeter, C. Loveday, R. M. Grant, V. A. Johnson, D. Kuritzkes, R. W. Shafer, and D. D. Richman. 2002. Drug resistance mutations in HIV-1. Top. HIV Med. 10:21-25.
6. Dauber, D. S., R. Ziermann, N. Parkin, D. J. Maly, S. Mahrus, J. L. Harris, J. A. Ellman, C. Petropoulos, and C. S. Craik. 2002. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. 76:1359-1368.
7. DesJarlais, R. L., G. L. Seibel, I. D. Kuntz, P. S. Furth, J. C. Alvarez, P. R. Ortiz de Montellano, D. L. DeCamp, L. M. Babe, and C. S. Craik. 1990. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA 87:6644-6648.
8. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
9. Erickson, J., D. J. Neidhart, J. VanDrie, D. J. Kempf, X. C. Wang, D. W. Norbeck, J. J. Plattner, J. W. Rittenhouse, M. Turon, N. Wideburg, and et al. 1990. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533.
10. Fitzgerald, P. M., B. M. McKeever, J. F. VanMiddlesworth, J. P. Springer, J. C. Heimbach, C. T. Leu, W. K. Herber, R. A. Dixon, and P. L. Darke. 1990. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-Å resolution. J. Biol. Chem. 265:14209-14219.
11. Gschwend, D. A., and I. D. Kuntz. 1996. Orientational sampling and rigid-body minimization in molecular docking revisited: on-the-fly optimization and degeneracy removal. J. Comput.-Aided Mol. Des. 10:123-132.
12. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
13. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA panel. JAMA 279:1984-1991.
14. Hodge, C. N., P. E. Aldrich, L. T. Bacheler, C. H. Chang, C. J. Eyermann, S. Garber, M. Grubb, D. A. Jackson, P. K. Jadhav, B. Korant, P. Y. Lam, M. B. Maurin, J. L. Meek, M. J. Otto, M. M. Rayner, C. Reid, T. R. Sharpe, L. Shum, D. L. Winslow, and S. Erickson-Viitanen. 1996. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem. Biol. 3:301-314.
15. Hoffman, N., C. A. Schiffer, and R. Swanstrom. Virology, in press.
16. Jaskolski, M., A. G. Tomasselli, T. K. Sawyer, D. G. Staples, R. L. Heinrikson, J. Schneider, S. B. Kent, and A. Wlodawer. 1991. Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 30:1600-1609.
17. Kantor, R., R. Machekano, M. J. Gonzales, K. Dupnik, J. M. Schapiro, and R. W. Shafer. 2001. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 29:296-299.
18. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, et al. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
19. Kurt, N., W. R. Scott, C. A. Schiffer, and T. Haliloglu. 2003. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. Proteins 51:409-422.
20. Lam, P. Y., Y. Ru, P. K. Jadhav, P. E. Aldrich, G. V. DeLucca, C. J. Eyermann, C. H. Chang, G. Emmett, E. R. Holler, W. F. Daneker, L. Li, P. N. Confalone, R. J. McHugh, Q. Han, R. Li, J. A. Markwalder, S. P. Seitz, T. R. Sharpe, L. T. Bacheler, M. M. Rayner, R. M. Klabe, L. Shum, D. L. Winslow, D. M. Kornhauser, C. N. Hodge, et al. 1996. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J. Med. Chem. 39:3514-3525.
21. Lapatto, R., T. Blundell, A. Hemmings, J. Overington, A. Wilderspin, S. Wood, J. R. Merson, P. J. Whittle, D. E. Danley, K. F. Geoghegan, et al. 1989. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342:299-302.
22. Lattman, E. E., and W. E. Love. 1970. A rotational search procedure for detecting a known molecule in a crystal. Acta Crystallogr. Sect. B Struct. Sci. 26:1854-1857.
23. Leavitt, S., and E. Freire. 2001. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11: 560-566.
24. Markgren, P. O., M. Hamalainen, and U. H. Danielson. 1998. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Anal. Biochem. 265:340-350.
25. McPherson, A., Jr. 1976. The growth and preliminary investigation of protein and nucleic acid crystals for X-ray diffraction analysis. Methods Biochem. Anal. 23:249-345.
26. McRee, D. E. 1999. XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:156-165.
27. Meng, E. C., D. A. Gschwend, J. M. Blaney, and I. D. Kuntz. 1993. Orientational sampling and rigid-body minimization in molecular docking. Proteins 17:266-278.
28. Meng, E. C., B. K. Shoichet, and I. D. Kuntz. 1992. Automated docking with grid-based energy evaluation. J. Comp. Chem. 13:505-524.
29. Muzammil, S., P. Ross, and E. Freire. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631-638.
30. Navia, M. A., P. M. Fitzgerald, B. M. McKeever, C. T. Leu, J. C. Heimbach, W. K. Herber, I. S. Sigal, P. L. Darke, and J. P. Springer. 1989. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615-620.
31. Ohtaka, H., A. Velazquez-Campoy, D. Xie, and E. Freire. 2002. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11:1908-1916.
32. Oshiro, C. M., I. D. Kuntz, and J. S. Dixon. 1995. Flexible ligand docking using a genetic algorithm. J. Comput.-Aided Mol Des. 9:113-130.
33. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
34. Palmer, S., R. W. Shafer, and T. C. Merigan. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667.
35. Parikh, U., C. Calef, B. Larder, R. F. Schinazi, and J. W. Mellors. 2001. HIV sequence compendium, p. 191-277. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory Press, Los Alamos, N.Mex.
36. Perrakis, A., T. K. Sixma, K. S. Wilson, and V. S. Lamzin. 1997. wARP: improvement and extension of crystallographic phases by weighted averaging of multiple refined dummy atomic models. Acta Crystallogr. Sect. D Biol. Crystallogr. 53:448-455.
37. Pflugrath, J. W. 1999. The finer things in X-ray diffraction data collection. Acta Crystallogr. Sect. D Biol. Crystallogr. 55:1718-1725.
38. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (Cambridge) 10:369-381.
39. Prabu-Jeyabalan, M., E. A. Nalivaika, N. M. King, and C. A. Schiffer. 2003. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J. Virol. 77:1306-1315.
40. Rutenber, E., E. B. Fauman, R. J. Keenan, S. Fong, P. S. Furth, P. R. Ortiz de Montellano, E. Meng, I. D. Kuntz, D. L. DeCamp, R. Salto, et al. 1993. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J. Biol. Chem. 268:15343-15346.
41. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:61-91.
42. Scott, W. R., and C. A. Schiffer. 2000. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Struct. Fold Des. 8:1259-1265.
43. Shafer, R. W., D. R. Jung, B. J. Betts, Y. Xi, and M. J. Gonzales. 2000. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 28:346-348.
44. Shafer, R. W., D. Stevenson, and B. Chan. 1999. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res. 27:348-352.
45. Sheldrick, G. M., and T. R. Schneider. 1997. SHELXTL: high resolution refinement. Methods Enzymol. 277:319-343.
46. Shoichet, B. K., D. L. Bodian, and I. D. Kuntz. 1992. Molecular docking using shape descriptors. J. Comp. Chem. 13:380-397.
47. Shoichet, B. K., and I. D. Kuntz. 1991. Protein docking and complementarity. J. Mol. Biol. 221:327-346.
48. Spinelli, S., Q. Z. Liu, P. M. Alzari, P. H. Hirel, and R. J. Poljak. 1991. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 73:1391-1396.
49. Stoll, V., W. Qin, K. D. Stewart, C. Jakob, C. Park, K. Walter, R. L. Simmer, R. Helfrich, D. Bussiere, J. Kao, D. Kempf, H. L. Sham, and D. W. Norbeck. 2002. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 10:2803-2806.
50. Vagin, A., and A. Teplyakov. 1997. MOLREP: an automated program for molecular replacement. J. Appl. Cryst. 30:1022-1025.
51. Velazquez-Campoy, A., Y. Kiso, and E. Freire. 2001. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390:169-175.
52. Velazquez-Campoy, A., M. J. Todd, and E. Freire. 2000. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry 39:2201-2207.
53. Vickrey, J. F., B. C. Logsdon, G. Proteasa, S. Palmer, M. A. Winters, T. C. Merigan, and L. C. Kovari. 2003. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification and crystallization. Protein Expr. Purif. 28:165-172.
54. Wallace, A. C., R. A. Laskowski, and J. M. Thornton. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134.
55. Wlodawer, A., M. Miller, M. Jaskolski, B. K. Sathyanarayana, E. Baldwin, I. T. Weber, L. M. Selk, L. Clawson, J. Schneider, and S. B. Kent. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
56. Wu, T. D., C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77:4836-4847.